*Please scroll down to the bottom of the page for the final deliverable.
What is the future of Parkinson's disease treatment?
While current treatments aimed at Parkinson's can make life more comfortable
They only touch the symptoms of the disease, while the underlying biological processes progressively deteriorate.
Neuropore Therapies' most advanced compound, NPT200-11 takes a more direct approach and attacks the disease itself.
In Parkinson's, evidence suggests that the disease is caused by misfolding of a single protein, alpha-synuclein.
When cells make large amounts of misfolded alpha-synuclein
The misfolded proteins form aggregates
Which disrupt normal cellular function and viability.
We designed and developed NPT200-11 to block association of alpha-synuclein with the cell's membrane, disrupting one of the earliest events that leads to disease symptoms.
In promising studies on animal models of Parkinson's
NPT200-11 improved motor performance
and the compound has since moved to clinical trials in 2015.
Structurally novel and orally bioavailable
NPT200-11 is a partnered asset that serves as just one example of what Neuropore's team can accomplish
With leading-edge drug discovery approaches.
Realize dreams through innovation. Overcome treatment limitations with us. Come explore solutions with us as a partner.